RECORD // Company

Lakewood-Amedex Biotherapeutics Inc.

Built 2026-11-22T01:01:41Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001213900-26-120790

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-1,474,7313 months ended 2026-09-3010-Q2026-11-160001213900-26-1207902026-11-22 01:01 UTCReport an error
Interest expense$48,8529 months ended 2026-09-3010-Q2026-11-160001213900-26-1207902026-11-22 01:01 UTCReport an error
Cash and cash equivalents$2,823,636at 2026-09-3010-Q2026-11-160001213900-26-1207902026-11-22 01:01 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0002079272
Ticker
LABT
EIN
205274304
CUSIP
51255A201
Record ID
sx:sec:0002079272

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

16 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
State of incorporationNV2026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
Business address8031 COOPER CREEK BLVD., SUITE 103, UNIVERSITY PARK, FL, 342012026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued (filed 2026-11-16)Listing Rule or Standard; Transfer of Listing. On November 10, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from September 29, 2026 through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Because the Company effected a 1-for-10 reverse stock split on June 22, 2026, within the prior one-year period, the Company is…2026-11-16SEC EDGAR 8-K 0001213900-26-120724 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-11-10)On November 4, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) entered into a Share Redemption Agreement, dated as of November 2, 2026 (the “Redemption Agreement”) with Shakawe Capital LLC (the “Holder”), the holder of all of the outstanding shares of the Company’s Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”). Under the Redemption Agreement, the Company agreed to redeem all 127,097 outstanding shares of Series C Preferred Stock for an aggregate redemption price of $1,270,970, equal to the face value of $10.00 per share, payable in cash from the Company’s available funds. From the date of the Redemption Agreement until closing…2026-11-10SEC EDGAR 8-K 0001213900-26-118127 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-10)On November 5, 2026, the Company issued a press release announcing the completion of the redemption. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.2026-11-10SEC EDGAR 8-K 0001213900-26-118127 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote (filed 2026-09-29)of Security Holders. On September 22, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the record date of July 30, 2026, there were 2,369,688 shares of Common Stock outstanding and entitled to vote. The following is a brief description of each matter voted upon at the Annual Meeting and the voting results. Proposal 1 - Election of Directors The Company’s stockholders elected each of the following nominees to serve as a director until the Company’s 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified: Nominee For Against Withhold Broker non-vote Kelvin…2026-09-29SEC EDGAR 8-K 0001213900-26-104177 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
Largest institutional holder #1 (13F as filed): Marex Group Ltd$151,2442026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #2 (13F as filed): UBS Group AG$12,8682026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #3 (13F as filed): Tower Research Capital LLC (TRC)$1,9592026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #4 (13F as filed): OSAIC HOLDINGS, INC.$4332026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #5 (13F as filed): HRT FINANCIAL LP$1402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #6 (13F as filed): Blue Trust, Inc.$352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.